Figures computed from official regulatory filings — .
Analysttarget 10 USD (+4999900%) · consensus 3/5 · 0 buy · 1 hold · 0 sell
Ownershipinsiders 0% · institutions 0% · short 2.2% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Evelo Biosciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
34 buys19 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Bodmer Mark | Exercise | n/a (No price was disclosed in the filing) | SEC | ||
| Thorell Marella |
| Exercise |
| n/a (No price was disclosed in the filing) |
| SEC |
| GILL SIMBA | Sell | $56.8 | SEC |
| McHale Duncan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bodmer Mark | Sell | $1K | SEC |
| GILL SIMBA | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bodmer Mark | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GILL SIMBA | Exercise | n/a (No price was disclosed in the filing) | SEC |
| McHale Duncan | Sell | $1K | SEC |
| McHale Duncan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Thorell Marella | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thorell Marella | Sell | $597.6 | SEC |
| McHale Duncan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bodmer Mark | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thorell Marella | Exercise | n/a (No price was disclosed in the filing) | SEC |
| McHale Duncan | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Thorell Marella | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bodmer Mark | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Bodmer Mark | Sell | $2.3K | SEC |
| McHale Duncan | Sell | $2.3K | SEC |
| Thorell Marella | Sell | $1.3K | SEC |
| GILL SIMBA | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GILL SIMBA | Sell | $7.9K | SEC |
| GILL SIMBA | Exercise | n/a (No price was disclosed in the filing) | SEC |
| GILL SIMBA | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |